NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
Clinical Trials
6 trialsNCT07450599 2026-03-05
CHINANEO
Bayer
Phase 2 Not yet recruiting
NCT05059236 2026-02-09
ARASEC
Bayer
Phase 2 Active not recruiting
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed